Objective-Human protein C is a plasma serine protease that plays a key role in hemostasis, and activated protein C (aPC) is known to elicit protective responses in vascular endothelial cells. This cytoprotective activity requires the interaction of the protease with its cell membrane receptor, endothelial protein C receptor. However, the mechanisms regulating the beneficial cellular effects of aPC are not well known. We aimed to determine whether a serine protease inhibitor called protease nexin-1 (PN-1) or serpinE2, expressed by vascular cells, can modulate the effect of aPC on endothelial cells. Approach and Results-We found that vascular barrier protective and antiapoptotic activities of aPC were reduced both in endothelial cells underexpressing PN-1 and in endothelial cells whose PN-1 function was blocked by a neutralizing antibody. Our in vitro data were further confirmed in vivo. Indeed, we found that vascular endothelial growth factormediated hyperpermeability in the skin of mice was markedly reduced by local intradermal injection of aPC in wild-type mice but not in PN-1-deficient mice. Furthermore, we demonstrated a previously unknown protective role of endothelial PN-1 on endothelial protein C receptor shedding. We provided evidence that PN-1 inhibits furin, a serine protease that activates a disintegrin and metalloproteinase 17 involved in the shedding of endothelial protein C receptor. We indeed evidenced a direct interaction between PN-1 and furin in endothelial cells. Conclusions-Our results thus demonstrate an original role of PN-1 as a furin convertase inhibitor, providing new insights for understanding the regulation of endothelial protein C receptor-dependent aPC endothelial protective effects.
A ctivated protein C (aPC) is a serine protease derived from its inactive zymogen, protein C. Endothelial protein C receptor (EPCR) is important for aPC activities. EPCR binds aPC and participates in the multiple protective responses of aPC mediated by signaling through the thrombin receptor, protease-activated receptor-1 (PAR-1), on cultured vascular endothelial cells. 1 Indeed, aPC exhibits significant anti-inflammatory activity 2 and can inhibit both staurosporininduced apoptosis 2 and thrombin-induced endothelial permeability. 3, 4 The regulation of aPC activity on endothelial cells is thus critical. Despite the importance of the beneficial cellular effects of aPC, the molecular mechanisms through which aPC mediates these effects remain incompletely understood. Protease nexin-1 (PN-1) or serpinE2, a serine protease inhibitor belonging to the serpin superfamily, is expressed in many different cells [5] [6] [7] and inhibits numerous proteases, playing key roles in hemostasis and thrombosis, including aPC. 8 We have shown that PN-1 expressed in vascular endothelial cells is able to regulate thrombin activity. 9 We thus investigated whether endothelial PN-1 could also modulate aPC activity. For this purpose, we used EAhy926 cells, an immortalized cell line produced by hybridization of human umbilical vein endothelial cells with lung carcinoma cells, A549. 10 This cell line has been largely used and reported to express the typical endothelial proteins over successive passages. 11 Esmon's group has demonstrated that EPCR is shed by a disintegrin and metalloproteinase (ADAM) named ADAM17 or tumor necrosis factor-α-converting enzyme.
12 ADAM17 is an important sheddase involved in the proteolysis of many membrane proteins, including tumor necrosis factor-α and its receptors. 13, 14 Importantly, a maturation process is required to render ADAM17 active. This essential step for ADAM17 activation is the proteolytic processing by a chymotrypsin-like serine protease, named furin, which belongs to the prohormone convertase family. 15, 16 Furin is involved in the activation and function of many proteins in almost all mammalian cell types. 17 Proteolytic activation of proteases mediated by furin can take place in the trans-Golgi network, in endosomes, and also at the cell surface. 18, 19 Furin has indeed been assigned to the Golgi apparatus, the endosomes, and the plasma membrane of endothelial cells. 20 Because both furin and PN-1 are present in endothelial cells, we investigated whether PN-1 could be a potential inhibitor of furin and demonstrated that formation of complexes between PN-1 and furin can indeed occur in endothelial cells, leading to an inhibition of ADAM17, consequently resulting in the protection of EPCR from shedding by the metalloproteinase. Taken together, our data bring to light an original PN-1-dependent mechanism by which EPCR shedding can be regulated.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

PN-1 Facilitates the Antiapoptotic Effect of aPC
aPC is known to mediate different cytoprotective effects, including antiapoptotic activity. 2 These cytoprotective activities of aPC require binding to EPCR and are mediated by signaling through the thrombin receptor PAR-1 1 or other PARs in some cases. 21 EAhy926 is the most studied and characterized permanent human vascular endothelial cell line, which is known to express EPCR and PAR-1. Staurosporin, an ATP analog and inhibitor of protein kinase C, is a well-known and potent inducer of apoptosis. As estimated here by terminal deoxynucleotidyl transferase dUTP nick end labeling staining and in agreement with previous results, 22, 23 the treatment of EAhy926 cells with aPC inhibited staurosporin-induced cell death ( Figure 1 ). We examined whether endothelial PN-1 can modulate such an effect. The cytoprotective effect of aPC was significantly inhibited when EAhy926 cells were incubated with a blocking anti-PN-1 antibody, whereas no change was observed with an irrelevant IgG ( Figure 1 ). The blocking anti-PN-1 antibody alone had no effect on staurosporin-induced apoptosis, indicating that blockade of PN-1 by itself had no effect on cell death.
PN-1 Facilitates the Endothelial Barrier Function Mediated by aPC
The cytoprotective activity of aPC was also analyzed on endothelial barrier integrity in a dual-chamber system. As previously described in this system, 3 thrombin induced an increase in cell permeability, which could be blocked by preincubation of cells with aPC. We showed that the capacity of aPC to enhance the barrier function in EAhy926 endothelial cells was inhibited when the cells were incubated with a blocking PN-1 antibody (Figure 2A ) or when endothelial PN-1 expression was knocked down with a PN-1-small interfering RNA (siRNA; Figure 2B ). Neither the blocking anti-PN-1 IgG alone nor the irrelevant IgG alone changed barrier disruption induced by thrombin, in the absence of aPC, under our experimental conditions (OD650=0.24±0.06 for anti-PN-1 IgG alone and 0.19±0.03 for irrelevant IgG alone versus 0.21±0.03 for the positive control). Our data showed for the first time that endothelial PN-1 facilitates the endothelial barrier function mediated by aPC.
We substituted factor Xa for aPC because factor Xa is also known to exhibit endothelial barrier protective function via the activation of PARs. 24 Interestingly, we observed that endothelial barrier activity remained protected when factor Xa was used to induce the endothelial barrier protection, either in cells preincubated with a blocking anti-PN-1 antibody ( Figure 2C ) or in cells transfected with a PN-1-siRNA ( Figure 2D ). The PN-1 effect is thus specific to aPC activity and may therefore act on the interaction of aPC with its endothelial receptor EPCR. To demonstrate such a potential link between PN-1 and EPCR and because EPCR is known to be strongly expressed in the large vessels of the lung, 25 the expression of EPCR in lung homogenates from mice was analyzed by immunoblotting. Interestingly, a significant reduction in EPCR expression was clearly observed in lung extracts from PN-1-deficient mice (PN-1 −/− ) compared with wild-type (WT) mice ( Figure 3A) , indicating that PN-1 plays a significant role in the regulation of EPCR expression.
To further define in vivo the potential role of the endogenous PN-1 in the endothelial barrier protection induced by aPC, dermal vascular hyperpermeability was measured in mice by the leakage of Evans blue in response to local intradermal injection of vascular endothelial growth factor (VEGF; modified Miles assay). Evans blue binds to plasma proteins and therefore extravasates along with them at sites of increased permeability. 26 As shown in Figure 3B , PN-1 −/− mice and their WT littermate showed similar leakage of Evans blue into sites injected with VEGF. As expected, local intradermal injection of aPC suppressed VEGF-mediated Evans blue dye extravasation in WT mice, confirming the endothelial barrier protective activity of aPC. This protective effect of aPC was remarkably abolished in PN-1 −/− mice. Indeed, in PN-1 −/− mice, the local injections of aPC had no significant effect on VEGF-induced Evans blue extravasation ( Figure 3B ). Taken together, our data point out the impact of vascular PN-1 on the protective effect of aPC.
Endothelial PN-1 Protects EPCR Shedding Induced by ADAM17
To investigate the mechanism by which endothelial PN-1 potentiates the activity of aPC, we analyzed EPCR expression in EAhy926 cells. Interestingly, we observed that PN-1-siRNA transfection in EAhy926 cells induced not only a strong reduction in PN-1 expression ( Figure 4A and 4B) but also a significant reduction in EPCR at the protein level ( Figure 4B ), without affecting EPCR mRNA levels ( Figure 4A) . Furthermore, as shown in Figure 4C and in the densitometric analysis of the corresponding results ( Figure 4D ), our data revealed that the reduction of EPCR observed in cells incubated with a neutralizing anti-PN-1 antibody or in cells transfected with PN-1-siRNA was accompanied by the presence of soluble EPCR in the conditioned medium of cells devoid of functional PN-1. Our data thus indicate that the presence of PN-1 on endothelial cells protects EPCR from shedding.
EPCR shedding is known to be mediated in endothelial cells by an important member of ADAM family, ADAM17, irrelevant IgG (20 µg/mL) before aPC or factor Xa treatment, followed by a 3-minute incubation with thrombin (5 nmol/L). Permeability was determined using Evans blue-labeled albumin in the upper chamber and measuring the optical density at 650 nm in the lower chamber (mean±SD; n=4-9 in duplicate; ***P<0.0001 compared with positive control). EAhy926 cells were transfected with irrelevant small interfering RNA (siRNA) or siRNA for PN-1 (PN-1-siRNA). After 3 days of incubation at 37°C, cells were incubated with (B) aPC and thrombin, as described above (mean±SD; n=3 in triplicate; **P<0.005 and *P<0.05 compared with positive control) or (D) factor Xa and thrombin, as described above (mean±SD; n=4 in triplicate; ***P<0.0001 and **P≤0.005 vs positive control). NS indicates nonsignificant.
also named tumor necrosis factor-α-converting enzyme. 12 We tested the effect of an inhibitor of ADAM17 on EPCR shedding in control cells and in cells devoid of functional PN-1. As shown in Figure 4E and in the densitometric analysis of the corresponding results ( Figure 4F ), shedding of EPCR was prevented if cells underexpressing PN-1 were treated with a synthetic inhibitor of ADAM17. Our data thus demonstrate that the presence of PN-1 in endothelial cells prevents the shedding of EPCR by ADAM17.
PN-1 Inhibits the Proteolytic Processing of ADAM17 by Furin
It is noteworthy that PN-1 belongs to the serpin family and has thus no direct inhibitory effect on ADAM such as ADAM17. ADAM17 is a membrane-anchored metalloproteinase that needs to be proteolytically processed to become active. 15, 16 We have shown by immunoblotting with an anti-ADAM17 antibody ( Figure 5A and 5B) that incubation of cells with a blocking anti-PN-1 antibody or transfection of cells with siRNA targeting PN-1 resulted in a significant decrease in the level of zymogen pro-ADAM17 compared with the data obtained for the respective control cells. Consistent with these in vitro observations, we observed by Western blots of mice lung extracts a decrease in the pro-ADAM17 band in PN-1 −/− mice compared with WT ( Figure I in the online-only Data Supplement). These data indicate that pro-ADAM17 maturation was increased in cells devoid of PN-1 and thus demonstrate that endothelial PN-1 acts to limit ADAM17 maturation.
ADAM proteinases are activated by proconvertases, including furin that was the first mammalian proconvertase identified. 27 Furin is expressed ubiquitously and has been shown to be involved in the maturation of pro-ADAM17. 15 Because furin is a serine protease, we hypothesized that PN-1 may regulate the proteolytic processing of pro-ADAM17 in EAhy926 cells by inhibiting endothelial furin. To verify this hypothesis, we tested the effect of an inhibitor of furin on pro-ADAM17 maturation in control cells and in cells devoid of functional PN-1. As shown in Figure 5A and in the densitometric analysis of the corresponding results ( Figure 5B ), the proteolytic processing of pro-ADAM17 observed in cells devoid of functional PN-1 was prevented when these cells were treated with the inhibitor of furin. Altogether, our data strongly suggest that PN-1 and furin are both involved in the maturation of pro-ADAM17 in endothelial cells. To consolidate the link between PN-1, furin, and EPCR shedding, we analyzed what happens to EPCR in the presence of furin inhibitor in control cells and in cells devoid of functional PN-1. As shown in Figure 5C and 5D, EPCR shedding observed in cells devoid of functional PN-1 is prevented when these cells were treated with furin inhibitor. Our data thus indicate that the presence of PN-1 in endothelial cells prevents the shedding of EPCR via a furin-dependent mechanism.
In Vitro Inhibition of Furin by PN-1
We demonstrated in vitro, by immunoblotting with anti-furin and anti-PN-1 antibodies, the formation of a covalent SDSstable complex of ≈110 kDa during incubation of recombinant PN-1 with recombinant furin ( Figure 6A ). The formation of the complex was prevented in the presence of furin inhibitor, indicating that furin activity was necessary for complex formation.
We confirmed that recombinant PN-1 was able to block recombinant furin by measuring the catalytic activity of furin toward PN-1) its fluorogenic substrate in the presence of increasing concentrations of PN-1. The catalytic activity of furin was decreased ≈2-fold in the presence of an equimolar concentration of PN-1 ( Figure 6B ). These data clearly indicate that furin is a potential target of PN-1.
PN-1 Colocalizes With Furin in Endothelial Cells
The physiological relevance of the interaction between PN-1 and furin was determined in endothelial cells by immunofluorescence using anti-PN-1 and anti-furin antibodies and confocal microscopic analysis. Double immunofluorescence revealed that furin colocalized with PN-1 both intracellularly and at the surface of endothelial cells ( Figure 6C ). To determine whether PN-1 and furin colocalization was caused by protein association, immunoprecipitation experiments were performed using the anti-furin antibody. In the control samples precipitated by the anti-furin antibody, a band at ≈110 kDa corresponding to PN-1-furin complexes was detected after blotting with both the anti-PN-1 and anti-furin antibodies ( Figure 6D ). Furthermore, treatment of cells with PN-1-siRNA resulted in a decreased intensity of the furin-PN-1 complex band in the immunoprecipitates, confirming that endogenous furin and endogenous PN-1 can form complexes in endothelial cells.
Discussion
Our results demonstrate a novel mechanism involving the serpin PN-1 and regulating the protection of the receptor EPCR from proteolytic cleavage. EPCR has been shown to be cleaved by neutrophil proteinase 3, which involves vascular injury and binding of activated neutrophils to endothelial cells. 28 EPCR has also been shown to be cleaved by ADAM17, in particular, in human umbilical vein endothelial cells because EPCR shedding was drastically reduced after knocking down ADAM17 expression in these cells. 12 Our data are the first to demonstrate that the shedding of EPCR can be regulated at the posttranslational level, upstream of ADAM17 action, by the cellular serpin PN-1. It cannot be excluded that factors other than ADAM17 may also account for PN-1-regulated shedding of EPCR. However, it is quite clear that PN-1 downexpression was accompanied by a marked downregulation of cell EPCR. PN-1 is a serpin that is barely detectable in plasma but is produced by most cell types and, in particular, by vascular cells. PN-1 is a powerful inhibitor of thrombin and plasminogen activators and has been revealed during this last decade to be an important regulator in the vascular system. 29 We demonstrated that PN-1 expressed by vascular cells regulates cell susceptibility to proteases of the coagulation and fibrinolytic systems. The importance of endothelial PN-1 was illustrated by the observation that PN-1 could inhibit thrombin activity on endothelial cells. 9 We thus analyzed the effect of endothelial PN-1 on aPC activity because aPC has also been shown, in vitro, to be inhibited by PN-1.
8 Surprisingly, we observed that the protective activity of aPC on endothelial cells is not inhibited by PN-1, but in contrast is favored by the presence of serpin in endothelial cells. The much lower kinetic parameters previously reported for the inhibition of aPC by PN-1 compared with those obtained for the inhibition of thrombin by PN-1 8 indicate clearly that if thrombin and aPC are both present on the endothelial surface, thrombin will be inhibited in preference to aPC.
The mechanism involved in such a regulation of EPCR proteolysis in endothelial cells is not direct because PN-1 is not an inhibitor of ADAM17. Actually, we demonstrated that this regulation results from PN-1 inhibition of pro-ADAM17 zymogen maturation by the proconvertase furin. To date, very few naturally occurring inhibitors of the proprotein convertase family have been reported in mammals. Those identified include 2 members of the serpin superfamily, an endogenous furin inhibitor released from human platelets named PI8 30 and the plasminogen activator inhibitor-1 (PAI-1) in the transfected human carcinoma LoVo and Hela cell lines. 31 We found here that PN-1 is also able to inhibit furin by forming SDSstable complexes with endogenous furin in endothelial cells. PAI-1 has also been shown to form an SDS-stable complex with furin, leading to a reduction in furin-dependent maturation and activity of the insulin receptor and pro-ADAM17. 31 However, in contrast to the present data, where overexpression of PN-1 was not required to demonstrate its effect on furindependent pro-ADAM17 maturation in endothelial cells, such an effect of PAI-1 has been shown in a heterologous expression system requiring transfection of LoVo cells with expression vectors containing both furin and PAI-1 coding sequences. Based on our results, we propose a model illustrated in Figure  II in the online-only Data Supplement in which endothelial PN-1 favors aPC cellular activities by preventing endogenous EPCR shedding.
Furin belongs to the group of specific mammalian proconvertases and cleaves various proteins. Interestingly, its catalytic triad aligns with that of thrombin in the chymotrypsin family of proteases. The crystal structures of PN-1 in complex with thrombin have been recently determined. 32 When looking at these crystal structures, it can be hypothesized that Arg346 present in the reactive center loop of PN-1 is the P1 residue for furin interaction, and Arg269 of PN-1 constitutes the other principal exosite contact interacting with furin. However, the tridimensional structure of PN-1 complexed with furin has to be established to verify the structural basis of furin recognition by PN-1. The fact that recombinant PN-1 could significantly inhibit the catalytic activity of recombinant furin, by forming SDS-stable complexes, is a direct proof that furin is a potential target for this serpin. Furthermore, PAI-1, which has the highest amino acid sequence homology with PN-1 among proteins of the serpin superfamily, has also been shown to inhibit furin. 31 Importantly, the fact that aPC requires vascular PN-1 to fully exert its cellular activities is physiologically relevant. Indeed, the impact of PN-1 on the cytoprotective activity of aPC has not only been shown in vitro on endothelial cells but also in vivo in mice because we demonstrated that the protective effect of aPC against VEGF-induced vascular hyperpermeability was drastically reduced in PN-1-deficient mice compared with the WT mice. Interestingly, in contrast, no difference was observed between the 2 types of mice concerning the basic hyperpermeability induced by VEGF, which clearly indicates that PN-1 does not act, under these experimental conditions, on the signaling induced by VEGF itself, but on the effect of aPC.
Our data show for the first time that endothelial PN-1 attenuates EPCR shedding and is thus a fundamental factor in the regulation of EPCR bioavailability. Therefore, PN-1 seems to be a new regulator in protease shedding processes. Because PN-1 is expressed in numerous cell types, its ability to regulate the shedding of various cell receptors may thus be of significance in many different fields. By such a capacity to control the expression of surface molecules, PN-1 seems a new factor in the regulatory step of receptor expression. In the field of hemostasis, such a role makes endothelial PN-1 an unexpected positive regulator of aPC biological responses. Because aPC and its receptor EPCR constitute a major physiological regulatory system controlling vascular wall responses not only during thrombosis but also during inflammation, our results present potential importance and possible relevance in strategies to improve the therapeutic efficacy of the aPC system in inflammatory diseases. PN-1) . A, Recombinant furin (rfurin) and recombinant PN-1 (rPN-1) were incubated in vitro in the absence or presence of the furin inhibitor (inhib) at 37°C for 90 minutes. The samples were separated on 10% SDS-PAGE and immunoblotted with anti-furin (IB: furin) or anti-PN-1 (IB: PN-1). The PN-1-furin complex was detected at 110 kDa. Immunoblots are representative of ≥3 independent experiments. B, Furin (0.65 µmol/L) was incubated with increasing concentrations of rPN-1 for 90 minutes. Furin inhibition was checked by measuring residual furin activity using its specific fluorogenic substrate Boc-RVRR-AMC: Boc-Arg-Val-Arg-Arg-amino-methylcoumarin-AMC (50 µmol/L; mean±SD; n=3; ***P<0.0001 and *P<0.05 vs control in the absence of PN-1). C, Confluent monolayers of EAhy926 cells, nonpermeabilized or permeabilized with 0.1% Triton X-100 for 10 minutes, were immunostained with anti-furin polyclonal antibody and anti-PN-1 monoclonal antibody, followed by Alexa 488-conjugated goat anti-rabbit IgG and Alexa 555-conjugated goat anti-mouse IgG. Immunofluorescence was analyzed by confocal microscopy. Merge corresponds to overlay of furin and PN-1 staining. Scale bar, 15 µm. D, EAhy926 cells were transfected with PN-1-small interfering RNA (siRNA) or irrelevant siRNA. Total cell protein extracts from treated EAhy926 cells were immunoprecipitated with the anti-furin monoclonal antibody, separated on 10% SDS-PAGE and immunoblotted with anti-furin (IB: furin) or anti-PN-1 (IB: PN-1) polyclonal antibodies and quantified by image analysis. A representative immunoblot is shown, and densitometric quantification is expressed as arbitrary densitometry units (mean±SD; n=5; **P<0.005 vs irrelevant siRNA).
Our study revealed that a serine protease inhibitor called protease nexin-1 (PN-1), or serpinE2, expressed by vascular cells, can be considered as a new player in the cytoprotective responses of activated protein C. Because activated protein C and its receptor endothelial protein C receptor constitute a major physiological regulatory system to control vascular wall responses to injury, the fact that vascular PN-1 favors activated protein C to exert its cellular activities is an original key finding, physiologically relevant. We also provided important very new insights regarding the mechanisms by which endothelial PN-1 modulates the cytoprotective effects of activated protein C. We indeed demonstrated that PN-1 can downregulate endothelial protein C receptor shedding by directly inhibiting the furin convertase present in endothelial cells. Because furin represents a processing enzyme of various cell surface receptors and growth factors, its inhibition by PN-1 opens new fields of investigation in many different disciplines.
Significance
